Organ and Functional Preservation Therapy of Selective Radiotherapy and Concomitant Intra-arterial Cisplatin for Patients with Locally Advanced Laryngeal Cancer

We investigated the treatment outcomes of 52 patients with locally advanced laryngeal squamous cell carcinoma (L-SCC) who were treated with selective radiotherapy and concomitant intra-arterial cisplatin (RADPLAT) at Kurume University Hospital between January 2006 and September 2016. Twenty-seven of the 52 patients had supraglottic cancer, 21 had glottic cancer, and 4 had subglottic cancer. The disease stages of the patients were as follows: Stage Ⅱ, n=8; Stage Ⅲ, n=33; and Stage Ⅳ-A, n=11. The 5-year locoregional control, disease-specific survival, and overall survival rates of all patients were 88%, 87%, and 82%, respectively. The 5-year freedom from laryngectomy, laryngectomy-free survival, and laryngo-esophageal dysfunction-free survival rates were 90%, 78%, and 76%, respectively. The incidence rates of grade >3 hematologic toxicities were as follows: leukopenia, 12% (n=6); neutropenia, 14% (n=7); and anemia, 4% (n=2). The incidence rates of non-hematologic toxicities were as follows: for mucositis, 4% (n=2); and dysphagia, 2% (n=1). RADPLAT was considered safe and feasible for patients with L-SCC and may have the advantage of achieving long-term larynx preservation.